Sunshine Biopharma Inc. (SBFM) Form 10-Q — Aug 13, 2026
Sunshine Biopharma reported Q2 2026 revenue of $9,263,687, down 1.6% year over year, with a net loss of $1,564,048 ($1.15 per share) versus a $1,770,834 loss ($3.94 per share) a year earlier. Gross margin compressed sharply to 26.2% from 36.4% as cost of sales rose on higher finished-goods costs, sales rebates, and inventory obsolescence. Cash stood at $13,748,301 at June 30, 2026, bolstered by a $6.0 million public offering on May 19, 2026 at $5.00 per unit and warrant exercises.
Key figures
- Revenue
- 9263687
- Revenue Yoy
- -1.6% (Q2 YoY); -5.2% six-month YoY
- Total Assets
- 33632901
- Cash Position
- 13748301
- Shares Outstanding
- 3877337
- Atm Program Cap
- 4000000
- Atm Shares Sold
- 1430521
- Atm Net Proceeds
- 1722555
- Six Month Revenue
- 17352452
- Cash Runway Months
- 27
- Total Liabilities
- 6094899
- Reverse Split Count
- 6
- Gross Margin Q2 2025
- 36.4%
- Gross Margin Q2 2026
- 26.2%
- Latest Reverse Split
- 1-for-10 effective June 1, 2026
- Chamoun Settlement CAD
- 1500000
- May2026 Offering Price
- $5.00 per unit
- Series BWarrant Strike
- $1.2202
- Series CWarrant Strike
- $2.50
- Series BWarrants Outstanding
- 25477133
- Series CWarrants Outstanding
- 4035540
- May2026 Offering Gross Proceeds
- 6000000
Price after filing
Close on the filing date to close N calendar days later (from $1.20). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.